巴斯夫收购普罗诺瓦生物制药，力争在欧米伽-3原药市场占据领先地位

Pharmadeals Review Pub Date : 2012-10-12 DOI:10.3833/PDR.V2012I12.1858

Heather Cartwright

{"title":"巴斯夫收购普罗诺瓦生物制药，力争在欧米伽-3原药市场占据领先地位","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I12.1858","DOIUrl":null,"url":null,"abstract":"In order to attain a leading position in the global omega-3 API market, the German chemical company BASF has made a voluntary offer to acquire Pronova BioPharma, the originator of the blockbuster omega-3 derived drug Lovaza®/Omacor® (omega-3-acid ethyl esters), for a total enterprise value of NOK4845 M (US$844 M). The deal follows BASF’s May 2012 acquisition of Equateq, a UK-based manufacturer of concentrated omega-3 fatty acids.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"62 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BASF Aims for Top Spot in Omega-3 API Market with Pronova BioPharma Acquisition\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2012I12.1858\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In order to attain a leading position in the global omega-3 API market, the German chemical company BASF has made a voluntary offer to acquire Pronova BioPharma, the originator of the blockbuster omega-3 derived drug Lovaza®/Omacor® (omega-3-acid ethyl esters), for a total enterprise value of NOK4845 M (US$844 M). The deal follows BASF’s May 2012 acquisition of Equateq, a UK-based manufacturer of concentrated omega-3 fatty acids.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"62 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-10-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2012I12.1858\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I12.1858","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

为了在全球omega-3原药市场占据领先地位，德国化工公司巴斯夫(BASF)自愿收购proprova BioPharma，该公司是畅销的omega-3衍生药物Lovaza®/Omacor®(omega-3-酸乙酯)的创始人，企业总价值为4845万挪威克朗(8.44亿美元)，此前巴斯夫于2012年5月收购了英国浓缩omega-3脂肪酸制造商Equateq。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

BASF Aims for Top Spot in Omega-3 API Market with Pronova BioPharma Acquisition

In order to attain a leading position in the global omega-3 API market, the German chemical company BASF has made a voluntary offer to acquire Pronova BioPharma, the originator of the blockbuster omega-3 derived drug Lovaza®/Omacor® (omega-3-acid ethyl esters), for a total enterprise value of NOK4845 M (US$844 M). The deal follows BASF’s May 2012 acquisition of Equateq, a UK-based manufacturer of concentrated omega-3 fatty acids.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pharmadeals Review

自引率

0.00%

发文量